AKT1 and cancer: While EML4-ALK has a driving role in activating downstream signalling cascades such as RAS/MAPK, PI3K/AKT and JAK/STAT3 in EML4-ALK-rearranged cancers, other proteins also feedback into those signalling pathways and might contribute to disease progression [5, 36].